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Summary
Introduction:  The  good  clinical  outcomes  and  low  wear  obtained  with  28-mm  metal-on-metal
implants  for  total  hip  replacement  prompted  the  development  of  large-diameter  heads  that
more closely  replicated  the  normal  hip  anatomy,  with  the  goal  of  improving  prosthesis  stability.
However, the  blood  release  of  metal  ions  due  to  wear  at  the  bearing  surfaces  and  the  high  rate
of groin  pain  seen  with  large-diameter  implants  are  causing  concern.  To  determine  whether
these events  are  related  to  the  geometry  and  metal  composition  of  the  prosthesis  components,
we conducted  a  prospective  study  of  clinical  outcomes  and  serum  chromium  and  cobalt  levels
1 year  after  implantation  of  three  different  acetabular  cups.
Hypothesis:  Serum  levels  of  metal  ions  are  comparable  with  different  types  of  large-diameter
metal-on-metal  total  hip  prostheses.
Patients  and  methods:  We  compared  24  DuromTM cups  (D),  23  M2a  MagnumTM cups  (M2a),  and  20
Conserve TotalTM (C)  cups  regarding  serum  chromium  and  cobalt  levels,  Postel-Merle  d’Aubigné
(PMA) scores  and  Oxford  Hip  Scores  (OHS),  as  well  as  radiographic  cup  orientation  and  position
at 1-year  follow-up.  Mean  age  was  66  years  (45—85  years),  mean  body  mass  index  was  28  Kg/m2
(18—45),  patients  were  almost  equally  divided  between  males  and  females,  and  the  reason  for
hip replacement  was  primary  hip  osteoarthritis  in  65  patients  and  avascular  necrosis  in  two.
Metal ions  were  assayed  in  serum  from  blood  drawn  through  non-metallic  catheters,  using  mass
spectrometry.
Results: Dislocation  occurred  in  two  patients  (one  D  and  one  M2a)  and  revision  to  change  the
bearing couple  was  required  in  two  patients  in  the  D  group.  Serum  cobalt  levels  in  the  C  group
were signiﬁcantly  higher  (P  =  0.  0003)  than  in  the  two  other  groups  (7.5  g/L  versus  2.  7  g/L
with D  and  2.  2  g/L  with  M2a).  Clinical  outcomes  were  better  in  the  M2a  group  (PMA,  17.7
[16—18]; and  OHS,  15.2  [12—30];  P  <  0.05).  The  PMA  score  and  OHS  were  17.5  (16—18)  and  18.2
(12—42), respectively,  with  D;  and  16.75  (10—18)  and  22.  2  (12—42),  respectively,  with  C  cups.
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When  all  three  cup  models  were  pooled,  serum  ion  levels  were  higher  in  patients  with  pain
than without  pain  (chromium,  7.1  g/L  versus  2.1  g/L  [P  =  0.002],  and  cobalt,  8  g/L  versus
2.6 g/L  [P  =  0.0004]).
Discussion:  Serum  chrome  and  cobalt  levels  increased  after  metal-on-metal  total  hip  replace-
ment, and  the  increase  was  greater  with  large-diameter  implants  than  previously  reported  with
28-mm implants.  Persistent  pain  was  signiﬁcantly  associated  with  higher  metal  ion  levels,  with
a probable  cobalt  cut-off  of  about  8  g/L.  Differences  in  modular  head-neck  concepts  may
explain the  observed  variations.
Level  of  evidence:  III,  prospective  comparative  study.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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etal-on-metal  (MOM)  implants  were  reintroduced  for  total
ip  replacement  (THR)  by  Weber  in  1988  [1]  based  on
he  excellent  outcomes  [2,3]  reported  with  ﬁrst-generation
OM  implants  [4]  and  on  the  recognition  that  failure  of
arly  MOM  implants  was  ascribable  to  early  aseptic  loosen-
ng  [5,6], tribologic  factors,  and  suboptimal  manufacturing
rocesses  [4,6]. The  excellent  outcomes  with  28-mm  MOM
mplants  led  to  the  development  of  larger-diameter  vari-
nts  with  the  goal  of  increasing  implant  longevity  [7]  and
iminishing  dislocation  rates  by  increasing  head  diameter
8].  MOM  implants  constitute  a  valuable  alternative  in  young
atients  with  high  levels  of  activity  [9—11]. The  cobalt-
hromium  alloys  used  for  MOM  implants  have  very  low
olumetric  wear  rates  but  nevertheless  release  metal  parti-
les  in  far  greater  amounts  than  do  metal-on-polyethylene
mplants  [12]. Released  metal  particles  undergo  oxidation,
eabsorption,  and  release  into  the  blood  [13]. Patients  with
OM  implants  have  higher  serum  levels  of  released  metal
ons  compared  to  patients  who  either  have  no  implants
r  have  cemented  or  cementless  metal-on-polyethylene  or
eramic  implants  [14]. The  passage  of  metal  ions  into  the
lood  has  raised  concern  about  possible  hypersensitivity
ssues,  carcinogenic  effects,  and  foetal  toxicity  in  pregnant
omen.  The  available  epidemiological  studies  have  failed
o  conﬁrm  these  suspected  adverse  effects  [15—25].
The  main  objective  of  this  prospective  comparative
on-randomised  study  was  to  compare  outcomes  with
hree  commercially-available  large-diameter  MOM  acetabu-
ar  cups  regarding  serum  levels  of  cobalt  (tCo)  and  chromium
tCr)  1  year  after  implantation,  with  the  goal  of  evaluating
he  impact  of  manufacturing  decisions  regarding  tribologic
eatures  and  modular  junctions.  Our  secondary  objectives
ere  to  assess  the  rate  of  persistent  pain  and  to  compare
linical  outcomes  across  implants.  Our  working  hypothe-
is  was  that  serum  metal  ion  levels  would  be  comparable
cross  the  three  total  hip  prosthesis  models  involving  large-
iameter  components  and  an  MOM  bearing  couple.
atients and methodsmplants
e  compared  three  monoblock  cups  made  of  high-carbon
obalt-chromium  alloys  designed  to  minimize  wear  [26]
i
w
T
cFig.  1).  (a).  The  DuromTM cup  is  a  forged  implant  shaped
s  a  truncated  165◦ hemisphere  designed  to  maximize  range
f  motion.  Primary  stability  is  ensured  by  press-ﬁt  ﬁxa-
ion  and  three  equatorial  ﬁns,  with  2  mm  of  press-ﬁt  at
he  equator  after  reaming  to  1  mm  above  the  size  of  the
up.  Secondary  stability  is  achieved  by  bony  ingrowth  into
 porous  titanium  surface  coating  (Porolock  Ti  VPS)  plasma
prayed  onto  the  alloy.  The  two-thirds  spherical  head  has  an
pen  design  when  head  size  is  50  mm  or  more,  to  decrease
eight.  Clearance  is  150   for diameters  of  38  to  56  mm
nd  slightly  greater  for  larger  diameters.  In  our  study,  the
urgeons  were  free  to  choose  between  a  cemented  stem
Contact  EvolutionTM [Wright,  Rueil  Malmaison,  France])  and
 non-cemented  stem  (ProFemur  LTM [Wright])  (Table  1).  The
itanium  pivot  and  modular  titanium  neck  constituted  an
dditional  interface  with  both  cemented  and  non-cemented
tems.  The  neck  could  be  long  or  short,  straight,  anteverted,
n  varus,  or  both  anteverted  and  in  varus.  The  cobalt-
hromium  adapter  sleeve  ensuring  the  junction  between
he  stem  and  head  was  available  in  three  lengths  (−4,  0
nd  +4  mm).  (b)  The  M2a  MagnumTM cup  (Biomet,  Valence,
rance)  is  a  cast  alloy  component  shaped  as  a  full  180◦ hemi-
phere  with  a  wall  thickness  of  7  mm  at  the  pole  and  4  mm
t  the  rim.  The  cup  is  secured  by  impaction  with  2  mm  of
ress-ﬁt.  Four  pairs  of  ﬁns  ensure  rotational  stability.  Sec-
ndary  stability  is  via  a  sprayed  coat  of  porous  titanium
overed  with  hydroxyapatite.  The  two-thirds  spherical  head
as  a closed  design,  regardless  of  size,  and  is  secured  to  the
tem  by  a titanium  adapter  sleeve  available  in  three  sizes
−3.5,  0  and  +3.5  mm).  Clearance  increases  from  the  small-
st  to  the  largest  cup  size,  from  75    to  150  .  In  our  study,
his  implant  was  consistently  used  with  a non-cemented
xceptionTM stem  (Biomet,  Valence,  France)  available  as
tandard  and  lateralized  offset  options.  (c)  The  Conserve
otalTM (Wright,  Rueil  Malmaison,  France)  is  also  a  cast
lloy  and  is  shaped  as  a  truncated  170◦ hemisphere.  It  is
ecured  with  1  mm  of  press-ﬁt  with  no  ﬁns.  Secondary  sta-
ility  is  obtained  using  a  porous  titanium  spray  without
dded  hydroxyapatite.  The  head  is  made  of  forged  alloy  and
as  an  open  design  across  the  range  of  sizes.  No  adapter
leeve  is  used,  because  each  head  diameter  is  available
n  three  neck  lengths  (−3.5  mm,  0  mm,  and  +3.5  mm).  In
ontrast  to  the  two  other  implants,  the  Conserve  TotalTM
mplant  has  a hemispherical  head.  In  our  study,  the  stems
ere  the  same  as  those  used  with  the  DuromTM implant.
able  1  reports  the  distribution  of  femoral  stems  by  type  of
up.
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Figure  1  The  three  cups  compared  in  this  study:  a:  DuromTM (Zimmer,  Etupes,  France);  b:  M2a  MagnumTM (Biomet,  Valence,
France); and  c:  Conserve  TotalTM (Wright,  Rueil  Malmaison,  France).
Table  1  Femoral  stems  and  junctions  used  with  each  type  of  acetabular  cup.  The  difference  was  statistically  signiﬁcant
(P =  2.2·10−6,  Fisher’s  exact  test).
Stem  Stem  ﬁxation  Stem  alloy  Neck  modularity  DuromTM (Cr-Co
sleeve)
MagnumTM
(Titanium
sleeve)
ConserveTM (no
sleeve)
Contact  EvolutionTM
(Wright,  Rueil
Malmaison,  France)
Cemented  Titanium  Modular  20  0  4
ProFemur LTM (Wright,
Rueil  Malmaison,
France)
Cementless  Titanium  Modular  4  0  16
ExceptionTM (Biomet, Cementless  Titanium  Monoblock  0  23  0
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Patients
Starting  in  May  2008,  all  patients  selected  for  THR  using
a  large-diameter  MOM  prosthesis  were  entered  into  the
study.  The  choice  of  the  implant  to  use  (DuromTM,  M2a
MagnumTM,  or  Conserve  TotalTM)  was  at  the  discretion  of  the
three  participating  surgeons  (PM,  AG  and  EH).  Patients  in
all  three  implant  groups  were  entered  consecutively  into
the  study.  There  were  24  patients  in  the  DuromTM group,
23  in  the  M2a  MagnumTM group,  and  20  in  the  Conserve
TotalTM group.  Exclusion  criteria  were  the  presence  of  other
metallic  implants  (joint  prostheses  or  internal  ﬁxation  hard-
ware),  dental  metal  cavity  ﬁllings,  and  renal  dysfunction.
Only  patients  undergoing  primary  hip  replacement  surgery
were  included.
The  postero-lateral  approach  was  used  in  all  patients.
Ideal  cup  position  was  deﬁned  as  40◦—45◦ abduction  and
20◦ anteversion  and  ideal  stem  position  as  15◦ antever-
sion.  Table  2  gives  the  demographic  details  of  the  three
groups.
MethodAfter  1  year  of  follow-up,  each  patient  had  a  blood  sam-
ple  drawn  through  a  non-metallic  intravenous  catheter  and
into  plastic  tubes  to  eliminate  contamination  by  contact
with  metal.  Cobalt  was  assayed  using  inductively  coupled
g
F
i
elasma  mass  spectrometry  [27,28]  and  chromium  using
tomic  absorption  spectrometry,  in  serum,  at  the  Amiens
eaching  Hospital,  France.  Results  were  given  in  microgram
er  litre  and  nanomolecule  per  litre.  Normal  values  were  less
han  0.53  g/L  (9  nmol/L)  for  cobalt  and  less  than  0.26  g/L
5  nmol/L)  for  chromium,  and  the  quantiﬁcation  limits  were
.02  g/L  (0.3  nmol/L)  and  0.05  g/L  (1  nmol/L),  respec-
ively.  Values  are  reported  as  median  (interquartile  range
nd  range),  in  compliance  with  current  recommendations
28]
Clinical  outcomes  1  year  after  surgery  were  assessed  via
he  Postel-Merle  d’Aubigné  (PMA)  score  [29]  and  a  patient
elf-questionnaires  to  determine  and  the  12-item  Oxford
ip  Score  (OHS)  [30]. In  each  group,  we  identiﬁed  patients
eporting  persistent  pain,  even  if  mild  or  intermittent,  which
as  sufﬁcient  to  affect  the  PMA  score.
An  anteroposterior  pelvis  radiograph  with  the  lower  limbs
n  15◦ of  internal  rotation  was  obtained  1  year  after  surgery.
n  the  acetabular  side  of  the  joint,  we  measured  cup  abduc-
ion  relative  to  the  tear-drop  line  and  we  located  the  centre
f  rotation  of  the  hip  using  the  concentric-circles  method.
n  the  femoral  side,  we  measured  femoral  offset  [31],
lobal  offset,  and  length  using  the  method  of  Ranawat  [32].
ll  these  measurements  were  performed  on  digital  radio-
raphs  using  ImagikaTM software  (View  Tec,  Saint-Maurice,
rance).  The  reference  value  was  the  known  diameter  of  the
mplanted  cup,  to  eliminate  error  due  to  the  ampliﬁcation
ffect  (Fig.  2).
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Table  2  Demographic  features  in  the  three  implant  groups.
Features  DuromTM MagnumTM ConserveTM
Number  of  patients  24  23  20
Males/females, n  10/14  9/14  11/9
Age in  years,  mean  (range)  67  (50—79)  67  (51—81)  65  (45—77)
BMI in  Kg/m2,  mean  (range)  27  (18—46)  29.6  (29—34)  26.6  (19—39)
Indication for  hip  replacement
Osteoarthritis 24  23  18
Femoral head  avascular  necrosis 0 0  2
BMI: body mass index.
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Figure  3  Serum  cobalt  levels  in  each  of  the  three  implant
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gigure  2  Radiographic  measurements  performed  using
magikaTM software  (ViewTeck,  Saint-Maur,  France).
tatistical  methods
he  statistical  analysis  was  performed  at  the  Biostatis-
ics  Department  of  the  Amiens  Teaching  Hospital,  Amiens,
rance,  using  SAS  9.2  (SAS,  Cary,  NC,  USA).  Quantita-
ive  variables  were  described  as  mean  ±  SD  and  range  or
s  median  and  qualitative  variables  as  percentage.  The
ruskal-Wallis  test  was  used  for  comparisons  of  quantita-
ive  variables  across  the  three  implant  groups.  Post  hoc
omparisons  were  with  the  Wilcoxon  test  and  Bonferroni
orrection.  Comparisons  of  qualitative  variables  across  the
hree  implant  groups  were  performed  by  means  of  the  Fisher
xact  test.  A  linear  regression  model  was  built  to  look  for
orrelations  between  metal  ion  levels  and  clinical  variables.
ogistic  regression  was  performed  to  assess  associations
etween  the  study  variables  and  pain.  Values  of  P  lower  than
.05  were  considered  signiﬁcant.esults
n  each  of  the  three  groups,  tCr  and  tCo  were  signiﬁcan-
ly  increased  compared  to  the  upper  limit  of  normal.  In
s
a
w
(roups.  The  data  are  median  (interquartile  range)  in  microgram
er litre.
he  overall  study  population,  tCo  was  2.9  g/L  (1.6—6.8)  or
0.9  nmol/L  (28.1—122.9)  and  tCr  was  2.2  g/L  (1.2—4.5)
r  42.1  nmol/L  (23—87).  Median  tCo  was  2.8  g/L  (1.3—6.6)
ith  DuromTM,  2.2  g/L  (1.4—3.1)  with  M2a  MagnumTM,
nd  7.5  g/L  (3.6—10.2)  with  Conserve  TotalTM.  Median
Cr  was  1.6  g/L  (1—2.4)  with  DuromTM, 2.5  g/L  with
2a  MagnumTM (1.9—3.8),  and  4.4  (1.4—6.3)  with  Conserve
otalTM (Figs.  3  and  4  and  Table  3).  The  tCo  values  varied
igniﬁcantly  across  the  three  implant  groups  (P  =  0.0003),
ith  signiﬁcantly  higher  levels  in  the  Conserve  TotalTM group
han  in  the  DuromTM and  MagnumTM groups.  The  difference
etween  the  MagnumTM and  DuromTM groups  was  not  statis-
ically  signiﬁcant.  The  tCr  values  varied  signiﬁcantly  across
he  three  implant  groups  (P  =  0.038).  The  values  were  sig-
iﬁcantly  lower  in  the  DuromTM group  than  in  the  Conserve
otalTM group.  No  statistically  signiﬁcant  differences  in  tCr
ere  found  between  the  DuromTM and  MagnumTM groups
r  between  the  MagnumTM and  Conserve  TotalTM groups
Table  3).
Table  4  reports  the  clinical  outcomes  in  the  three  implant
roups.  The  three  groups  were  comparable  in  terms  of
ample  size,  age,  sex  distribution,  body  mass  index  (BMI),
nd  reason  for  THR.  After  1  year,  the  mean  PMA  score
as  17.3  ±  1.2  (10—18)  and  the  mean  OHS  was  19.2  ±  9.6
12—42).  The  clinical  scores  in  the  M2a  MagnumTM group
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Table  3  Serum  levels  of  cobalt  and  chromium  in  the  three  implant  groups.
Serum  levels  DuromTM M2a  MagnumTM Conserve  TotalTM
Median  (interquartile  range)
Cobalt
g/L  2.76  (1.31—6.57)  2.24  (1.42—3.13)  7.5  (3.6—10.2)a
nmol/L  47.5  (22.5—137.5)  38.5  (24.5—53.9)  129.6  (68.1—186.4)a
Chromium
g/L  1.6 (1.01—2.42)b 2.51 (1.86—3.79) 4.4 (1.4—6.3)
nmol/L 30.5 (19.5—46.5)b 52.2 (36.6—72.7) 85 (26.7—120.4)
a Serum cobalt levels were signiﬁcantly higher with Conserve TotalTM than with DuromTM and M2a MagnumTM (no signiﬁcant difference
between these last two cups).
b Serum chromium levels were signiﬁcantly lower with DuromTM than with Conserve TotalTM. No signiﬁcant differences were found
between DuromTM and M2a MagnumTM or between Conserve TotalTM and M2a MagnumTM.
Table  4  Clinical  outcomes  in  the  three  outcome  groups.
Clinical  scores  DuromTM M2a  MagnumTM Conserve  TotalTM
PMA  score  17.5  ±  0.7  (16—18)  17.7  ±  0.5  (16—18)  16.7  ±  1.8  (10  —18)
Oxford Hip  Score  18.2  ±  8.5  (12—42)  15.2  ±  6.4  (12—30)  22.9  ±  10.1  (12—42)
The data are mean (range). A signiﬁcant difference was found across the three groups (P = 0.02, Kruskal-Wallis test). Post-hoc analyses
showed a signiﬁcant difference between M2a MagnumTM and Conserve TM
between DuromTM and M2a MagnumTM (P = 0.22) or between DuromTM a
Figure  4  Serum  chromium  levels  in  each  of  the  three  implant
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vgroups.  The  data  are  median  (interquartile  range)  in  microgram
per litre.
were  signiﬁcantly  better  than  in  the  Conserve  TotalTM group
(P  =  0.02)  and  non-signiﬁcantly  better  than  in  the  DuromTM
group.  Clinical  outcomes  in  the  DuromTM group  were  non-
signiﬁcantly  better  than  in  the  Conserve  TotalTM group  and
non-signiﬁcantly  worse  than  in  the  M2a  MagnumTM group
(Table  4).Three  patients  experienced  postoperative  complications.
Anterior  dislocation  occurred  on  the  day  of  surgery  in  a
patient  in  the  M2a  MagnumTM group.  After  external  reduc-
tion,  there  was  no  recurrence  and  the  clinical  result  was
p
r
m Total (P = 0.008, Wilcoxon test) with no signiﬁcant difference
nd Conserve TotalTM (P = 0.11). PMA: Postel-Merle d’Aubigné.
xcellent  (PMA,  18;  and  OHS,  12).  In  a  patient  in  the
onserve  TotalTM group  who  had  persistent  pain,  posterior
islocation  occurred  after  about  1  year  (at  follow-up  the
MA  score  was  16  and  the  OHS  score  was  32).  Finally,  another
atient  in  the  Conserve  TotalTM group  experienced  common
bular  nerve  palsy  that  resolved  incompletely,  leading  to  a
oor  clinical  outcome  (PMA  at  10;  and  OHS  at  42).  At  a  dis-
ance  from  the  primary  procedure,  persistent  pain  required
evision  surgery  in  two  patients  in  the  DuromTM group,  after
3  and  22  months,  respectively.
Of  the  67  patients,  24  (35.8%)  reported  persistent  groin
ain  after  THR.  The  pain  was  mild  and  consistent  with
ormal  activities  in  17  (25.4%)  patients  (PMA  pain  score,
/6),  moderate  in  six  (8.9%)  patients  (PMA  pain  score,
/6),  and  severe  in  a  single  (1.5%)  patient  (PMA  pain
core,  <  4/6).  Mean  PMA  score  in  patients  reporting  no  pain
as  17.9  ±  0.3  (16—18),  compared  to  16.3—1.5  (10—18)  in
atients  reporting  persistent  pain  (P  =  3.5·10−8).  Mean  OHS
as  15.8  ±  5.5  (12—33)  and  24.4  ±  11.1  (12—42)  in  these  two
roups,  respectively  (P  =  0.005).  Table  5  lists  the  types  of
ain  recorded  in  each  implant  group.  The  ConserveTM group
ad  a  higher  number  of  patients  reporting  pain  than  did  the
agnumTM group  (P  =  0.009)  and  the  DuromTM group  (P  =  0.08,
on-signiﬁcant).  No  signiﬁcant  difference  in  pain  preva-
ence  was  found  between  the  DuromTM and  M2a  MagnumTM
roups  (P  =  0.38,  non-signiﬁcant).  No  patient  had  radiolucent
eriacetabular  lines  or  implant  migration.  No  signiﬁcant  dif-
erences  were  found  across  the  three  implants  regarding
erticalisation  or  mean  implant  diameter  (Table  6).Table  7  reports  the  metal  ion  concentrations  in  the
atients  with  persistent  pain.  Compared  to  patients
eporting  no  pain,  those  reporting  pain  of  even  the
ildest  intensity  had  a  non-signiﬁcantly  higher  median
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Table  5  Prevalence  and  intensity  of  persistent  pain  in  each  of  the  three  implant  groups.
Pain  intensity  Overall  population  (n  =  67)  DuromTM (n  =  24)  MagnumTM (n  =  23)  ConserveTM (n  =  20)
Mild  17  (25.4%)  6  (25%)  4  (17.4%)  7  (35%)
Moderate 6  (8.9%)  2  (8.3%)  0  4  (20%)
Severe 1  (1.5%)  0  0  1  (5%)
Total 24  (35.8%)  8  (33.3%)  4  (17.4%)  12  (60%)a
Pain was assessed using the Postel-Merle d’Aubigné pain score. A signiﬁcant difference was found for the overall prevalence of persistent
pain (P = 0.0071, Fisher’s exact test).
a Persistent pain was signiﬁcantly more common with Conserve TotalTM than with DuromTM or M2a MagnumTM. The difference between
DuromTM and M2a MagnumTM was not statistically signiﬁcant.
Table  6  Radiographic  outcomes  in  the  three  implant  groups.  The  data  are  mean  (range).
Variables  DuromTM M2a  MagnumTM Conserve  TotalTM
Cup
Diameter  (mm)  ns  53.4  (48;60)  51  (44;58)  53.8  (46;62)
Abduction (◦)  ns  50.9  (38;58)  47.7  (25;59)  48.8  (34;60)
Centre of  rotation  x  (mm)  ns  30.6  (26;38)  31.5  (23;40)  28.9  (23;37)
Centre of  rotation  y  (mm)  P  =  0.005  14.3  (9;24)  14.1  (7.7;37)  15.6  (10;20)
Teardrop cup  rim  distance  (mm)  ns  5.4  (−3.8;  +  11.1)  0.7  (−10.8;8.3)  3.1  (−2.8;8.1)
Femur
Femoral offset  (mm)  ns  36.6  (17;46)  42.8  (33.6;56.7)  39.7  (25;50)
Length (mm)  ns  32.8  (11;43)  31.9  (13;45)  32  (18;50)
Variation in  femoral  offset  (mm)  ns  +2.9  (−11;  +  19)  +4.5  (−13;  +  19)  +2.0  (−5;  +  11)
Variation in  global  offset  (mm)  ns  +3.2  (−11;  +  23)  +1.5  (−16;  +  15)  +0.2  (−11;  +  13)
Variation in  length  (mm)  ns  +0.8  (−14;  +  15)  −0.7  (−17;  +  19)  +0.03  (−8.5;  +  8.4)
tCo  value  (6.4  g/L  versus  2.6  g/L).  When  only  patients
with  moderate-to-severe  pain  were  considered,  the  differ-
ence  was  statistically  signiﬁcant  (8  g/L  versus  2.6  g/L,
P  =  0.002).  The  median  tCr  level  was  2.1  g/L  in  the  patients
reporting  no  pain,  2.55  g/L  in  those  reporting  pain  of  any
intensity  (P  =  0.07,  non-signiﬁcant),  and  7.1  g/L  in  those
reporting  moderate-to-severe  pain  (P  =  0.0004).  The  tCo  and
tCr  values  did  not  correlate  signiﬁcantly  with  age,  sex,  body
weight,  implant  size,  femoral  offset,  length,  global  offset,
Table  7  Serum  metal  ion  levels  in  patients  with  and
without  persistent  pain.  The  data  are  median  (range)  in
microgram  per  litre.
Pain  category  Overall  population
No  pain
n  of  patients  43
Cobalt  2.6  (1.4—3.8)
Chromium  2.1  (1.1—3.5)
Pain of  any  intensity
n  of  patients 24
Cobalt  6.45  (1.9—9.5)
Chromium 2.55  (1.4—5.9)
Moderate-to-severe  pain
n of  patients 7
Cobalt 8.3  (7.21—10.4)  P  =  0.002
Chromium  7.1  (5.7—8.2)  P  =  0.0004
or  use  of  a  modular  femoral  component.  The  strongest  cor-
relations  with  tCo  and  tCr  levels,  in  order  of  decreasing
strength,  were  with  the  PMA  score  (negative  correlation),
persistent  pain,  BMI  (negative  correlation),  patient  height,
and  cup  abduction.  Figs.  5  and  6  show  tCo  and  tCr  values  by
cup  abduction  and  cup  size.
In  patients  with  mild  pain,  no  investigations  were  per-
formed  to  determine  the  source  of  pain,  as  the  clinical
outcomes  were  nevertheless  excellent  in  this  subgroup.  In
the  DuromTM group,  the  ﬁrst  patient  to  report  moderate  pain
had  a  tCo  value  of  6.9  g/L,  a  tCr  value  of  5.4  g/L,  a  BMI
of  26.2  Kg/m2,  and  52.4◦ of  cup  abduction.  Her  C-reactive
μ
Figure  5  Serum  cobalt  levels  (g/L)  by  cup  abduction  (◦):
positive  correlation.
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Table  8  Patients  with  persistent  pain  in  the  Conserve  TotalTM group.
Features Patient  #1  Patient  #2  Patient  #3  Patient  #4  Patient  #5
Sex  M  F  F  M  F
BMI 29.3  21.6  39.5  18.7  35.2
Cup abduction  58.8◦ 53.3◦ 51.4◦ 52.4◦ 51.6◦
Cup  size  62  54  54  54  54
Serum Co  (g/L)  10.7  7.5  5.8  10.1  2.8
Serum Cr  (g/L)  7.1 5.9 0.6 9.1  0.8
Suggested
diagnosis
Psoas
tendinitis
Delayed posterior
dislocation
Collection  in  the
psoas  muscle
None,  watchful
waiting
Common  ﬁbular
nerve  palsy
BMI: body mass index.
μ
Figure  6  Serum  cobalt  levels  (g/L)  by  cup  size  diameter
(mm):  no  correlation.
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Figure  7  Intraoperative  evidence  of  metallosis  upon  revision  surge
persistent pain  (courtesy  of  Henri  Migaud,  Lille  Teaching  Hospital,  Lrotein  level  was  normal  and  aspiration  of  the  hip  recovered
terile  radiopaque  ﬂuid.  Her  skin  prick  tests  for  metal  allergy
ere  positive.  Computed  tomography  (CT)  of  the  hip  was
nremarkable.  Revision  surgery  was  performed  to  implant
 ceramic-on-ceramic  prosthesis  and  to  collect  pathological
pecimens.  Histology  showed  a  predominantly  lymphoplas-
acytic  inﬂammatory  inﬁltrate  in  a  perivascular  distribution
nd  a  few  metal  particles.  In  the  second  DuromTM patient
eporting  moderate  pain,  tCo  was  97.7  g/L,  tCr  45.6  g/L,
MI  22.2  Kg/m2, and  cup  abduction  56.8◦. As  with  the  previ-
us  patient,  investigations  for  infection  were  negative  and
he  CT-scan  unremarkable.  Revision  surgery  to  change  the
earing  couple  was  performed  at  a  different  institution.
bnormal  mobility  was  found  between  the  adapter  sleeve
ry  in  the  second  DuromTM patient  reporting  clinically  signiﬁcant
ille,  France).
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bigure  8  Computed  tomography  showing  a  hematoma  in  the
soas muscle  of  patient  #3.
nd  head,  as  well  as  marked  metallosis  (Fig.  7).  None  of  the
atients  in  the  M2a  MagnumTM group  reported  substantial
ain,  and  none  required  revision  surgery.  In  the  Conserve
otalTM group,  ﬁve  patients  reported  moderate-to-severe
ain.  Their  main  features  are  reported  in  Table  8.  The  poor
linical  outcome  in  patient  #5  was  directly  ascribable  to
bular  nerve  palsy.  The  other  four  patients  had  excessive
up  verticalization  and  high  tCo  and  tCr  values.  In  none  of
hese  four  patients  was  the  source  of  pain  clearly  identi-
ed.  Patient  #3  had  lower-limb  venous  compression  related
o  a  collection  within  the  psoas  muscle  in  contact  with  the
ip  (Fig.  8).  To  date,  none  of  these  patients  has  requested
evision  surgery.  In  the  overall  study  population,  the  exis-
ence  of  persistent  pain  did  not  correlate  with  age,  sex,
ody  weight,  or  lower-limb  lengthening.  In  contrast,  per-
istent  pain  correlated  with  patient  height,  implant  size,
Co,  tCr,  femoral  offset  (negative  correlation),  global  offset
negative  correlation),  and  cup  abduction.
iscussion
obalt  and  chromium  release  into  the  bloodstream  var-
ed  across  the  three  types  of  cup  evaluated  in  our  study.
elease  was  signiﬁcantly  lower  with  M2a  MagnumTM than
ith  DuromTM and  Conserve  TotalTM.  The  clinical  outcomes
ere  consistent  with  the  metal  ion  data:  the  M2a  MagnumTM
roup  had  signiﬁcantly  better  PMA  score  and  OHS  values  and
igniﬁcantly  fewer  patients  with  persistent  pain  after  THR.
he  tCo  values  correlated  with  the  PMA  score,  persistent
ain,  BMI,  patient  height,  and  cup  abduction.  Persistent  pain
as  signiﬁcantly  associated  with  higher  tCo  values,  and  the
ata  suggested  that  tCo  values  in  excess  of  8  g/L  might  be
ssociated  with  an  increased  risk  of  persistent  pain.
One  source  of  bias  in  our  study  was  the  small  number
f  patients  in  each  group.  However,  we  had  more  than  20
atients  per  group,  which  allowed  us  to  perform  appropriate
tatistical  tests.  Second,  we  did  not  obtain  data  on  changes
n  metal  ion  values  over  time  in  a  given  patient.  Finally,
ifferences  occurred  across  the  three  groups  regarding  the
istribution  of  femoral  stems  and  the  use  of  the  stems  by
he  three  different  surgeons.  The  DuromTM and  Conserve
otalTM cups  were  used  with  modular  necks,  whereas  the  M2a
agnumTM cup  was  not.  However,  neck  modularity  occurred
t  a  titanium-on-titanium  interface,  where  potential  wear
g
f
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ould  have  had  little  impact  on  our  assay  results.  Thus,  our
ata  chieﬂy  reﬂect  wear  at  the  bearing  couple,  and  the  inﬂu-
nce  of  the  head-neck  interface  should  not  have  inﬂuenced
ur  results.
In  patients  without  implants  or  with  ceramic-on-ceramic
mplants,  tCo  and  tCr  are  undetectable  [13]. With  MOM
mplants  measuring  28  mm  in  diameter,  the  serum  levels  are
ear,  or  slightly  lower  than,  1  g/L  [13,33]. No  signiﬁcant
ifferences  have  been  reported  between  28-mm  MOM  THR
nd  resurfacing  [34]. Resurfacing  with  DuromTM was  associ-
ted  with  cobalt  levels  of  0.67  g/L  in  a  study  by  Vendittoli
t  al.  [35]  and  0.95  g/L  in  a  study  by  Pattyn  et  al.  [36].
 comparison  by  Garbuz  et  al.  [37]  of  levels  with  DuromTM
esurfacing  and  DuromTM THR  showed  a  larger  increase  with
HR  (46-fold  versus  10-fold  the  normal  value)  related  to
he  existence  of  modular  components  in  the  THR  prosthe-
is.  Lavigne  et  al.  [38]  compared  serum  metal  ion  levels  with
our  types  of  large-diameter  MOM  implants.  They  reported
ncreases  similar  to  those  found  in  our  study,  again  with
ower  values  in  the  M2a  MagnumTM group.  Interestingly,  the
ncreases  were  not  larger  than  those  seen  after  total  knee
eplacement,  a procedure  that  is  not  generating  as  much
oncern  regarding  the  use  of  cobalt-chromium  alloys  [39].
uetzner  et  al.  [39]  measured  cobalt  and  chromium  levels
n  18  patients  with  cemented  unilateral  THR  after  a  mean
ollow-up  of  66  months  and  in  23  patients  with  bilateral
HR  after  a  mean  follow-up  of  50  months.  The  cobalt  level
as  3.28  g/L  in  the  unilateral  THR  group  and  4.28  g/L
n  the  bilateral  THR  group.  These  values  were  higher  than
hose  found  in  most  patients  after  large-diameter  MOM  THR
36—39].
In  the  ﬁrst  study  seeking  to  identify  safe  serum  cobalt
nd  chromium  levels,  MacDonald  [40]  reviewed  occupational
xposure  data.  They  found  that  the  safe  limit  in  the  event
f  occasional  exposure  was  15  g/L  [41]  but  recognized  the
eed  for  clinical  studies  of  patients  with  metal  implants.  In  a
ore  recent  study  of  26  patients  undergoing  revision  surgery
.9  years  on  average  after  resurfacing,  De  Smet  et  al.  [42]
ound  strong  correlations  linking  serum  and  joint  metal  ion
evels,  head  wear,  and  evidence  of  metallosis  at  revision.
obalt  levels  greater  than  19  g/L  were  associated  with  the
evelopment  of  metallosis  [42]. In  our  study,  cobalt  levels
bove  the  far  lower  threshold  of  8  g/L  were  associated  with
ersistent  pain.  The  impact  of  excessive  cup  verticalization
emonstrated  in  our  study  is  consistent  with  data  from  De
aan  et  al.  [43].
Several  hypotheses  may  explain  the  differences  across
up  types.  First,  the  M2a  MagnumTM adapter  sleeve  is  made
f  titanium  and  therefore  limits  the  chrome-cobalt  sur-
ace  area  on  which  passive  corrosion  can  occur,  thereby
iminishing  the  release  of  chromium  and  cobalt  ions  at  this
nterface.  This  factor  has  been  suggested  by  Lavigne  et  al.
38]  as  a  cause  of  differences  across  cups.  In  addition,  the
arger  diameter  of  the  MagnumTM adapter  sleeve  probably
ecreases  rotational  friction  of  the  head  on  the  adapter
leeve.  The  DuromTM cup  has  the  thinnest  wall,  of  only  4  mm,
3.7  mm  of  alloy  +  0.3  mm  of  titanium).  This  feature  may
e  associated  with  increased  susceptibility  to  deformities
enerated  during  cup  impaction  and,  therefore,  to  greater
riction  at  the  interface.
In  addition  to  metal  ion  release,  persistent  pain  is  of
oncern  after  large-diameter  MOM  THR  and  can  require
ular
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revision  to  change  the  bearing  couple.  Persistent  pain  may
be  related  to  a  variety  of  mechanisms.  Aseptic  lymphocytic
vasculitis-associated  lesion  [20,44]  occurred  in  1  to  2%  of
patients  in  a  study  by  Thomas  et  al.  [45]. Fluid-ﬁlled  or
solid  pseudotumours  may  develop  [46], requiring  surgical
revision  for  tissue  excision  and  a  change  in  the  bearing  cou-
ple  [47]. Pseudotumour  development  is  the  most  dreaded
complication  after  MOM  hip  arthroplasty.  One  study  sup-
ports  a  link  between  pseudotumours  and  increased  serum
cobalt  levels  after  resurfacing  [47]. Similarly,  an  association
between  persistent  pain  and  excessive  cup  verticalization
was  demonstrated  by  Berton  et  al.  [48]  after  DuromTM cup
implantation  for  THR.  In  our  study,  persistent  pain  corre-
lated  positively  with  patient  height,  implant  size,  and  serum
cobalt  and  chromium  levels  and  negatively  with  femoral  off-
set,  global  offset,  and  cup  abduction.
None  of  the  patients  in  our  M2a  MagnumTM group  had
clinically  signiﬁcant  pain.  In  contrast,  of  the  ﬁve  patients
reporting  moderate-to-severe  pain  in  the  Conserve  TotalTM
group,  four  (80%)  had  abnormalities  suggesting  an  adverse
reaction  to  metallic  debris  at  the  1-year  evaluation.  Revi-
sion  surgery  was  performed  in  2  (8.4%)  patients  in  the
DuromTM group.  Similarly,  Illgen  et  al.  [49]  found  that  11.1%
of  patients  required  a  change  in  the  bearing  couple  after  1
year  because  of  persistent  pain,  in  agreement  with  results
by  Berton  et  al.  [48]. Langton  et  al.  [50,51]  studied  failure
of  resurfacing  or  MOM  THR  in  660  patients.  After  a  mean
follow-up  of  41  months,  3.4%  of  patients  had  required  revi-
sion  surgery  for  persistent  pain.
Conclusion
This  comparison  of  three  large-diameter  MOM  hip  prostheses
identiﬁed  differences  in  serum  cobalt  and  chromium  lev-
els.  The  levels  were  lowest  with  the  M2a  MagnumTM cup.
However,  serum  cobalt  and  chromium  levels  with  all  three
cups  were  higher  than  those  reported  with  Metasul  28  mm
(about  1  g/L).  The  advantages  of  MOM  implants  for  THR
should  be  weighed  against  our  ﬁndings  of  clinically  signiﬁ-
cant  persistent  pain  in  10.4%  of  patients  and  of  signiﬁcantly
increased  serum  levels  of  cobalt  (P  =  0.002)  and  chromium
(P  =  0.0004)  1  year  after  surgery.  The  source  of  persistent
pain  remains  unclear  but  may  involve  adverse  reactions  to
metal  debris  released  at  foci  of  surface  wear  or  at  modular
junctions.  We  believe  that  implantation  of  MOM  hip  prosthe-
ses  is  a  demanding  procedure  that  must  meet  strict  criteria
for  acetabular  cup  positioning.
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